2023-05-16-世界卫生组织-ACT-Accelerator_Transition_Report_42页_1mb

ACT-Accelerator Transition Report (01 October 2022 to 31 March 2023) - Summary

Introduction

• State of the Global COVID-19 Pandemic: By March 2023, COVID-19 was still declared a Public Health Emergency of International Concern (PHEIC). Despite declining cases and deaths in most regions, the virus continued evolving, particularly the Omicron variant family. Cases surged in China in late 2022, leading to a rapid decline afterward.
• Global Tool Procurement:
  • Vaccines: Over 1.94 billion doses shipped to 146 countries, with COVAX donating 80 million doses.
  • Therapeutics: US$29.5 million worth of COVID-19 medicines procured, with US$410.7 million awarded for oxygen supplies.
  • Diagnostics: 193 million tests procured, with US$1 billion awarded by the Global Fund.
  • PPE: US$940.6 million worth procured, with US$767 million funded by the Global Fund.

Transition Plan Objectives

1. Focus R&D and market shaping

• Bivalent Vaccines: WHO SAGE approved bivalent COVID-19 vaccines for booster doses. CEPI invested in broader-coverage and stable vaccines.
• Market Diversification: Gavi, UNICEF, and partners promoted equitable vaccine access, while Unitaid supported generic manufacturing and pricing for diagnostics and therapeutics.

2. Secure institutional arrangements

• Long-term Financing: The Pandemic Vaccine Pool’s US$2.7 billion allocated, with US$24 billion committed by donors. COVAX transitioned to Gavi’s COVID-19 program for 2024-2025.
• Integration into Health Systems: C19RM extended to 2025, supporting oxygen infrastructure, surveillance, and community health workers. Vacuum Delivery Support funded integration into routine immunization (e.g., US$1 billion by Gavi).

3. Concentrate on new tools and priority populations

• Primary Vaccination Coverage: AMC92 countries increased primary coverage from 31% to 55%. 34 low-coverage countries saw their rates rise 9-fold to 27%.
• Test-to-Treat: Global Fund, Unitaid, and ACT-A partners established mechanisms for early detection and treatment of high-risk cases.
• Oxygen Access: UNICEF and Unitaid advanced local oxygen production, with 13,000 concentrators delivered.

Coordination and Future Directions

Coordination Mechanisms

• The ACT-A Tracking and Monitoring Task Force monitored progress, while the Health Systems and Response Connector streamlined health infrastructure support.
• Further Commitments: CEPI, FIND, and WHO strengthened R&D and surveillance; UNICEF ensured diverse diagnostics procurement through 2025.

Way Forward

• Continued COVID-19 Work: Larize integration of tools into routine health programs, preserving emergency readiness.
• Pandemic Preparedness: Contributions to global coordination platforms (e.g., CEPI’s 100 Days Mission, Global Oxygen Alliance) to enhance response to future threats.

Key Achievements

• Financing: US$24 billion pledged, with US$2.7 billion disbursed.
• Access:
  • Vaccines: 1.94 billion doses shipped, 55% primary coverage in AMC92.
  • Diagnostics: Over 193 million tests procured, WHO introduced PCR/Ag-RDT standards.
  • Therapeutics: 15 million antiviral courses delivered, affordable generic pricing maintained.
  • Oxygen: US$605 million awarded for oxygen systems, 4,461 concentrators delivered.
• Integration: Gavi’s CDS supported health system upgrades (cold chains, immunization registries) in 57 countries.

Annex (Q4 2022 and Q1 2023 Highlights)

• Data confirms rapid progress in tool delivery, infrastructure strengthening, and policy updates. Future operations hinge on regional manufacturing, equitable access, and behavioral interventions.